EGFR and neoplasm: Tyrosine kinase inhibitors (TKIs) that act against the EGFR (EGFR-TKIs), such as gefitinib, the first selective EGFR-TKI domain, can effectively prevent tumor growth, metastasis [1–3], and angiogenesis, and promote tumor cell apoptosis [4–6].